

**Amendments to the Claims:**

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

**In the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. to 4. (Canceled)
5. (Currently Amended) A method for evaluating a change in susceptibility of an HIV reverse transcriptase inhibitor for a second anti-HIV therapy comprising:
  - (i) receiving a sample from an HIV-infected patient who has been treated with a first anti-HIV therapy;
  - (ii) determining whether said sample from said HIV-infected patient comprises an HIV reverse transcriptase having ~~at least one~~ a mutation at the position 194, wherein the wild type amino acid glutamate is mutated to glycine (E194G) as compared to the wild-type HIV strain IIIB/LAI;
  - (iii) introducing said reverse transcriptase inhibitor for said second anti-HIV therapy to said sample from said HIV-infected patient containing said mutation;
  - (iv) determining the susceptibility of said HIV having said reverse transcriptase mutation of step (ii) to said HIV reverse transcriptase inhibitor in said sample;
  - ~~(iv)~~ comparing the anti-HIV drug effectiveness in said sample containing said reverse transcriptase mutation with a sample not containing such said mutation; and
  - ~~(v)~~ correlating the presence of said ~~at least one~~ reverse transcriptase mutation of step (ii) to a change in the susceptibility of said HIV reverse transcriptase inhibitor.